Correspondence 0001193125-24-030958 from Q32 Bio Inc. (QTTB)
Q32 Bio Inc.
Date: Feb. 12, 2024 · CIK: 0001661998 · Accession: 0001193125-24-030958
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276093
Referenced dates: February 9, 2024
Letter
200 Clarendon Street
Boston, Massachusetts 02116
Tel: +1.617.948.6000 Fax: +1.617.948.6001
www.lw.com
FIRM / AFFILIATE OFFICES
Austin
Milan
Beijing
Munich
Boston
New York
Brussels
Orange County
Century City
Paris
Chicago
Riyadh
February 12, 2024
Dubai
San Diego
Düsseldorf
San Francisco
Frankfurt
Seoul
Hamburg
Silicon Valley
Hong Kong
Singapore
Houston
Tel Aviv
London
Tokyo
VIA EDGAR DELIVERY
Los Angeles
Washington, D.C.
Madrid
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Cindy Polynice
Joe McCann
Tracie Mariner
Angela Connell
Re: Homology Medicines, Inc.
Amendment No. 1 to Registration Statement on Form S-4
Filed January 29, 2024
File No. 333-276093
Ladies and Gentlemen:
On behalf of Homology Medicines, Inc., a Delaware corporation (the “Company”), we are providing this letter in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) by letter dated February 9, 2024 (the “Comment Letter”) with respect to the Company’s Amendment No. 1 to Registration Statement on Form S-4, as filed on January 29, 2024 (“Amendment No. 1”).
In connection with this letter responding to the Comment Letter, the Company is concurrently filing Amendment No. 2 to the Company’s Registration Statement on Form S-4 (“Amendment No. 2”), which reflects certain revisions to Amendment No. 1 in response to the Comment Letter, as well as certain other changes.
For ease of review, we have set forth below each of the numbered comments of the Comment Letter in bold type, followed by the Company’s responses thereto. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in Amendment No. 2 and all references to page numbers in such responses are to page numbers in Amendment No. 2.
February 12, 2024
Page
Amendment No. 1 to Form S-4 Filed January 29, 2024
Cover Page
1. We note your response to our prior comment 1. Given that the Nasdaq listing condition is waivable, please further revise your disclosure to indicate whether recirculation or resolicitation of shareholders will occur prior to the vote if the listing application is not approved but the condition is waived. If Homology shareholders will not have certainty regarding the listing of the combined company’s shares at the time they are asked to vote, please clarify this fact. Please also provide risk factor disclosure that addresses the potential consequences of the parties waiving the condition and the closing occurring without the Nasdaq listing, including but not limited to the liquidity implications thereof.
Response: In response to the Staff’s comment, the Company has revised the disclosure on the cover page and on pages 45 and 189 of Amendment No. 2.
Homology is currently subject to securities class action litigation and may be subject to similar..., page 79
2. We note your response to our prior comment 11 and reissue in part. Please revise your disclosure to clarify whether damage awards could impact CVR payments.
Response: In response to the Staff’s comment, the Company has revised the disclosure on page 79 of Amendment No. 2.
* * *
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (617) 948-6018 with any questions or comments regarding this correspondence.
Very truly yours,
/s/ Elisabeth M. Martin
Show Raw Text
CORRESP 1 filename1.htm CORRESP 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh February 12, 2024 Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Silicon Valley Hong Kong Singapore Houston Tel Aviv London Tokyo VIA EDGAR DELIVERY Los Angeles Washington, D.C. Madrid United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Cindy Polynice Joe McCann Tracie Mariner Angela Connell Re: Homology Medicines, Inc. Amendment No. 1 to Registration Statement on Form S-4 Filed January 29, 2024 File No. 333-276093 Ladies and Gentlemen: On behalf of Homology Medicines, Inc., a Delaware corporation (the “Company”), we are providing this letter in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) by letter dated February 9, 2024 (the “Comment Letter”) with respect to the Company’s Amendment No. 1 to Registration Statement on Form S-4, as filed on January 29, 2024 (“Amendment No. 1”). In connection with this letter responding to the Comment Letter, the Company is concurrently filing Amendment No. 2 to the Company’s Registration Statement on Form S-4 (“Amendment No. 2”), which reflects certain revisions to Amendment No. 1 in response to the Comment Letter, as well as certain other changes. For ease of review, we have set forth below each of the numbered comments of the Comment Letter in bold type, followed by the Company’s responses thereto. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in Amendment No. 2 and all references to page numbers in such responses are to page numbers in Amendment No. 2. February 12, 2024 Page 2 Amendment No. 1 to Form S-4 Filed January 29, 2024 Cover Page 1. We note your response to our prior comment 1. Given that the Nasdaq listing condition is waivable, please further revise your disclosure to indicate whether recirculation or resolicitation of shareholders will occur prior to the vote if the listing application is not approved but the condition is waived. If Homology shareholders will not have certainty regarding the listing of the combined company’s shares at the time they are asked to vote, please clarify this fact. Please also provide risk factor disclosure that addresses the potential consequences of the parties waiving the condition and the closing occurring without the Nasdaq listing, including but not limited to the liquidity implications thereof. Response: In response to the Staff’s comment, the Company has revised the disclosure on the cover page and on pages 45 and 189 of Amendment No. 2. Homology is currently subject to securities class action litigation and may be subject to similar..., page 79 2. We note your response to our prior comment 11 and reissue in part. Please revise your disclosure to clarify whether damage awards could impact CVR payments. Response: In response to the Staff’s comment, the Company has revised the disclosure on page 79 of Amendment No. 2. * * * We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (617) 948-6018 with any questions or comments regarding this correspondence. Very truly yours, /s/ Elisabeth M. Martin Elisabeth M. Martin of LATHAM & WATKINS LLP cc: Paul Alloway, Ph.D., President and Chief Operating Officer, Homology Medicines, Inc. Jodie Morrison, President and Chief Executive Officer, Q32 Bio Inc. Peter N. Handrinos, Esq., Latham & Watkins LLP Leah R. Sauter, Esq., Latham & Watkins LLP Kingsley L. Taft, Esq., Goodwin Procter LLP Sarah Ashfaq, Esq., Goodwin Procter LLP